BIVI—(-69%/PM)—on data-integrity issue in phase-3 trial: https://www.globenewswire.com/news-release/2023/11/29/2787674/0/en/BioVie-Announces-Efficacy-Data-from-Phase-3-Trial-of-NE3107-in-Patients-with-Mild-to-Moderate-Alzheimer-s-Disease.html The data-integrity issue was disclosed three weeks ago in a 10-Q filing (#msg-173192871), so the magnitude of today’s selloff is curious.